Pfenex And Hospira Announce Collaboration To Develop And Commercialize Proposed LUCENTIS® Biosimilar

SAN DIEGO and LAKE FOREST, Ill., Feb. 10, 2015 -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, and Hospira, Inc., (HSP), the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, today announced that the companies have entered into an agreement to exclusively develop and commercialize for worldwide sales PF582, Pfenex's biosimilar candidate to Genentech's LUCENTIS® (ranibizumab injection). LUCENTIS had estimated global sales of approximately $4 billion in 2014 and is part of the broader $6.7 billion intraocular anti-VEGF (vascular endothelial growth factor) therapeutic segment.

Published: 10 February 2015
Written by Editor
AMEX   Up on News   Project Update  
Read more: Pfenex Inc ( PFNX )

Anthera Pharmaceuticals Announces Completion of Interim Analysis from Phase 3 Trial with Blisibimod for Systemic Lupus Erythematosus

-- CHABLIS-SC1 study passes futility analysis and will continue to completion with an enhanced endpoint
-- Enrollment to be completed in 2015 with final data in Q3 2016
-- Recent encouraging EMA feedback on BRIGHT-SC design to be incorporated prior to interim

HAYWARD, Calif., Feb. 10, 2015 -- Anthera Pharmaceuticals, Inc. (ANTH) today announced the successful completion of an interim analysis of its Phase 3 trial (CHABLIS-SC1) of blisibimod in patients with Systemic Lupus Erythematosus and that the study should continue to completion as planned. An independent statistician conducted the interim futility analysis for the CHABLIS-SC1 study, evaluating the SRI-6 response at the 24 week time point. Enrollment in the trial is projected to conclude in mid-2015.

Published: 10 February 2015
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Anthera Pharmaceuticals Inc ( ANTH )

Portola's Factor Xa Inhibitor Betrixaban Successfully Passes Futility Analysis in Phase 3 APEX Study; Trial Continues as Planned and Remains on Track for Enrollment Completion by Year-End

Betrixaban Has the Potential to be the First Approved Therapy for Hospital-to-Home Prevention of Fatal Blood Clots for the Over 20 Million High-Risk Acute Medically Ill Patients

SOUTH SAN FRANCISCO, Calif., Feb. 5, 2015  -- Portola Pharmaceuticals (PTLA) today announced that the Independent Data Monitoring Committee (IDMC) recommended that the Phase 3 APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) Study of betrixaban continue as planned without modification based on the successful completion of a pre-specified futility analysis. In making this recommendation, the IDMC evaluated preliminary efficacy trends and safety reports from the first half of the study. The APEX Study is assessing betrixaban, an oral, once-daily, investigational Factor Xa inhibitor, for both hospital and post-discharge prevention of venous thromboembolism (VTE), or blood clots, in acute medically ill patients. Acute medically ill patients are those who are hospitalized for serious medical conditions, such as heart failure, stroke, infection and pulmonary disease.

Published: 06 February 2015
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Portola Pharmaceuticals ( PTLA )

Biocept Introduces New Test for Patients With Non-Small Cell Lung Cancer

Company launches blood-based 'liquid biopsy' to identify ROS1 rearrangement and better inform NSCLC treatment decisions

SAN DIEGO, Jan. 20, 2015 -- Biocept, Inc. (BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and Circulating Tumor Cells (CTCs), today announced the launch of ROS1 testing on CTCs, which will help physicians identify which of their patients may be receptive to certain drugs for the treatment of non-small cell lung cancer.

Biocept's new blood test identifies chromosomal rearrangements of the gene encoding ROS1 proto-oncogene receptor tyrosine kinase (ROS1), thereby defining a distinct molecular subgroup of NSCLCs. Patients with ROS1-positive tumors may be receptive to a number of therapeutic options that inhibit this target.

Published: 06 February 2015
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Biocept Inc ( BIOC )

Can-Fite Completes Phase II/III Trial for CF101 in Treatment of Psoriasis

Data expected to be released in Q1 2015

PETACH TIKVA, Israel, Feb. 4, 2015  -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (CFBI.TA), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that all patients enrolled in its Phase II/III psoriasis trial for the Company's drug candidate CF101 have completed the study's 32 week treatment protocol. The trial has been completed and the final data is ready for analysis. The Company plans to publish top line results by the end of March 2015.  Interim results from this Phase II/III trial and final results from the prior Phase II trial for CF101 in psoriasis were both positive.  

Published: 04 February 2015
Written by Editor
AMEX   Up on News   Project Update  
Read more: Can-Fite BioPharma Ltd ( CANF )
  1. Theralase Technologies Inc ( TLT )
  2. Esperion Therapeutics Inc ( ESPR )
  3. Zogenix Inc ( ZGNX )
  4. ImmunoGen Inc ( IMGN )
  5. Spark Therapeutics ( ONCE )